Becton Dickinson to Sell Clontech in Q2 or Q3, Official Says; Buyer Remains Undisclosed
Becton Dickinson expects to complete the sale of its Clontech division in the second or third quarter, the company said last week.
“The process is moving ahead according to schedule,” Vince Forlenza, president of BD Biosciences, said at the JPMorgan Healthcare Conference, held here this week.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
